NO20070726L - Koblede pyrimidoner anvendbare i behandling eller forebygging av kreft - Google Patents

Koblede pyrimidoner anvendbare i behandling eller forebygging av kreft

Info

Publication number
NO20070726L
NO20070726L NO20070726A NO20070726A NO20070726L NO 20070726 L NO20070726 L NO 20070726L NO 20070726 A NO20070726 A NO 20070726A NO 20070726 A NO20070726 A NO 20070726A NO 20070726 L NO20070726 L NO 20070726L
Authority
NO
Norway
Prior art keywords
cancer
useful
pyrimidones
prevention
coupled
Prior art date
Application number
NO20070726A
Other languages
English (en)
Norwegian (no)
Inventor
Michael Howard Block
Audrey Davies
Maria-Elena Theoclitou
Daniel John Russell
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20070726L publication Critical patent/NO20070726L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO20070726A 2004-07-22 2007-02-08 Koblede pyrimidoner anvendbare i behandling eller forebygging av kreft NO20070726L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59024604P 2004-07-22 2004-07-22
PCT/GB2005/002845 WO2006008523A1 (fr) 2004-07-22 2005-07-21 Pyrimidones fusionnees utiles dans le traitement et la prevention du cancer

Publications (1)

Publication Number Publication Date
NO20070726L true NO20070726L (no) 2007-02-15

Family

ID=35253804

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070726A NO20070726L (no) 2004-07-22 2007-02-08 Koblede pyrimidoner anvendbare i behandling eller forebygging av kreft

Country Status (15)

Country Link
US (1) US20070287703A1 (fr)
EP (1) EP1773830A1 (fr)
JP (1) JP2008506759A (fr)
KR (1) KR20070044458A (fr)
CN (1) CN101023082A (fr)
AU (1) AU2005263969A1 (fr)
BR (1) BRPI0513513A (fr)
CA (1) CA2574204A1 (fr)
IL (1) IL180278A0 (fr)
MX (1) MX2007000809A (fr)
NO (1) NO20070726L (fr)
RU (1) RU2007106552A (fr)
UA (1) UA84954C2 (fr)
WO (1) WO2006008523A1 (fr)
ZA (1) ZA200700227B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US20100120717A1 (en) 2006-10-09 2010-05-13 Brown Jason W Kinase inhibitors
CA2702922C (fr) 2007-10-19 2018-01-16 Schering Corporation Derives de 1,3,4-thiadiazole spiro-condenses pour inhiber l'activite de la kinesine ksp
US20110033461A1 (en) * 2008-03-12 2011-02-10 Vladimir Ratushny Combination Therapy for the Treatment of Cancer
PL2448938T3 (pl) * 2009-06-29 2014-11-28 Incyte Holdings Corp Pirymidynony jako inhibitory PI3K
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
WO2011130342A1 (fr) 2010-04-14 2011-10-20 Incyte Corporation Dérivés condensés en tant qu'inhibiteurs de ρi3κδ
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
JP5961187B2 (ja) 2010-12-20 2016-08-02 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉ３ｋ阻害剤としてのｎ−（１−（置換フェニル）エチル）−９ｈ−プリン−６−アミン
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
HUE030869T2 (en) 2011-09-02 2017-06-28 Incyte Holdings Corp Heterocyclic amines as inhibitors of PI3K
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
WO2015191677A1 (fr) 2014-06-11 2015-12-17 Incyte Corporation Dérivés d'hétéroarylaminoalkylphényle bicycliques à titre d'inhibiteurs de pi3k
AU2016222556B2 (en) 2015-02-27 2020-08-27 Incyte Holdings Corporation Salts of Pl3K inhibitor and processes for their preparation
WO2016183063A1 (fr) 2015-05-11 2016-11-17 Incyte Corporation Formes cristallines d'un inhibiteur de pi3k
WO2016183060A1 (fr) 2015-05-11 2016-11-17 Incyte Corporation Procédé de synthèse d'un inhibiteur de phospho-inositide 3-kinases
WO2019055832A1 (fr) * 2017-09-15 2019-03-21 The Regents Of The University Of California Compositions et procédés d'inhibition de la n-smase2

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7230000B1 (en) * 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US6809102B2 (en) * 2001-03-29 2004-10-26 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
US7060705B2 (en) * 2001-11-07 2006-06-13 Merck & Co., Inc. Mitotic kinesin inhibitors
US6753428B2 (en) * 2001-11-20 2004-06-22 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
US7262186B2 (en) * 2001-12-06 2007-08-28 Merck & Co., Inc. Substituted pyrazolo[3,4-d] pyrimidinones as a mitotic kinesin inhibitor
EP1465896A4 (fr) * 2001-12-06 2006-01-11 Merck & Co Inc Inhibiteurs mitotiques de la kinesine
EP1481077B1 (fr) * 2001-12-06 2009-11-04 Merck & Co., Inc. Inhibiteurs mitotiques de la kin sine
WO2003049678A2 (fr) * 2001-12-06 2003-06-19 Merck & Co., Inc. Inhibiteurs mitotiques de la kinesine
BR0309278A (pt) * 2002-04-17 2005-04-26 Cytokinetics Inc Composto, composição, métodos para modular a atividade da cinesina ksp, para inibir a ksp, para o tratamento de uma doença proliferativa celular, e, uso de um composto
CA2485148A1 (fr) * 2002-05-09 2003-11-20 Cytokinetics, Inc. Composes, compositions et procedes
AU2003270015A1 (en) * 2002-05-09 2003-12-02 Cytokinetics, Inc. Compounds, compositions, and methods
AU2003265242A1 (en) * 2002-05-23 2003-12-22 Cytokinetics, Inc. Compounds, compositions, and methods
US6949538B2 (en) * 2002-07-17 2005-09-27 Cytokinetics, Inc. Compounds, compositions, and methods
JP2006515886A (ja) * 2003-01-17 2006-06-08 サイトキネティクス・インコーポレーテッド 化合物、組成物、および方法
US7022850B2 (en) * 2003-05-22 2006-04-04 Bristol-Myers Squibb Co. Bicyclicpyrimidones and their use to treat diseases
US7345046B2 (en) * 2003-05-30 2008-03-18 Chiron Corporation Heteroaryl-fused pyrimidinyl compounds as anticancer agents
MXPA05013142A (es) * 2003-06-20 2006-03-17 Chiron Corp Compuestos de piridinio [1,2-a]pirimidin-4-ona como agentes anticancer.
EP1670456A2 (fr) * 2003-10-06 2006-06-21 Cytokinetics, Inc. Composes, compositions et procedes
US20050148593A1 (en) * 2003-11-07 2005-07-07 Gustave Bergnes Compounds, compositions, and methods
US20050158320A1 (en) * 2003-11-12 2005-07-21 Nichols M. J. Combinations for the treatment of proliferative diseases
US7501416B2 (en) * 2004-02-06 2009-03-10 Bristol-Myers Squibb Company Quinoxaline compounds and methods of using them
AU2005233576A1 (en) * 2004-04-06 2005-10-27 Novartis Vaccines And Diagnostics, Inc. Mitotic kinesin inhibitors
MX2007004699A (es) * 2004-10-19 2007-06-14 Novartis Vaccines & Diagnostic Derivados de indol y bencimidazol.

Also Published As

Publication number Publication date
US20070287703A1 (en) 2007-12-13
RU2007106552A (ru) 2008-08-27
WO2006008523A1 (fr) 2006-01-26
EP1773830A1 (fr) 2007-04-18
KR20070044458A (ko) 2007-04-27
CN101023082A (zh) 2007-08-22
ZA200700227B (en) 2008-05-28
IL180278A0 (en) 2007-07-04
BRPI0513513A (pt) 2008-05-06
AU2005263969A1 (en) 2006-01-26
JP2008506759A (ja) 2008-03-06
UA84954C2 (ru) 2008-12-10
CA2574204A1 (fr) 2006-01-26
MX2007000809A (es) 2007-03-21

Similar Documents

Publication Publication Date Title
NO20070726L (no) Koblede pyrimidoner anvendbare i behandling eller forebygging av kreft
NO20074634L (no) Substituerte heterocykler og deres anvendelse som CHK1-, PDK1- og PAK-inhibitorer
NO20081454L (no) Met-kinaseinhibitorer
NO20071246L (no) Kinazolinonderivater og deres anvendelse som B-RAF-inhibitorer.
NO20063449L (no) Substituerte heterocykler og deres anvendelse
NO20071776L (no) Kinoksaliner som B RAF inhibitorer.
NO20075992L (no) Forbindelser som modulerer C-Kit og C-FMS aktivitet og anvendelser derav
WO2005002552A3 (fr) Composes pharmaceutiques
NO20076460L (no) Nye fluorenderivater, sammensetninger inneholdende nevnte derivater og anvendelse derav
TN2009000128A1 (en) Dihydropyridine derivatives useful as protein kinase inhibitors
EA200800555A1 (ru) Производные ксантина в качестве селективных агонистов hm74a
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
NO20081434L (no) 5-(fenylisoksazolyletoksy)-triazol-3-yl substituert pyridinsammensetninger for behandling av neurologisk, psykiatrisk eller smerteforstyrrelser
EA200600689A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов raf киназы
NO20070081L (no) Sulfamat og sulfamidderivater for behandling av epilepsi og relaterte sykdommer
NO20060230L (no) Nye aminobenzofenonforbindelser
NO20070656L (no) 2,4,6-Trisubstituerte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse ved behandling av kreft
NO20072461L (no) Fremstilling og anvendelse av bifenyl-4-yl-karbonylaminosyre derivater for behandling av fedme
EA200801372A1 (ru) Способы получения замещенных пиримидинов
NO20072747L (no) Fremgangsmate for fremstilling av indazolforbindelser
NO20084502L (no) Tetrahydropyrrolopyrimidinedioner og deres anvendelse som humane neutrofil elastase inhibitorer
MX2009011211A (es) Indoles sustituidos en la posicion 7 inhibidores de mci-1.
DK1519724T3 (da) Fredericamycin-derivater som lægemidler til behandling af tumorer
TW200611695A (en) Pyrrolopyridine derivatives
NO20084749L (no) Organiske forbindelser og deres anvendelser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application